EDT is decent after Beaufort was hired as CROBut a raise is inevitable, there will be no other buyer except Baxter, but Baxter seems to have got everything they need
Further dilution
Readout of the trials has to be very good, Baxter has to grab it faster
Cannot decide, might just sideline and watch